IBD Drug Entyvio By Takeda Pharmaceuticals Is Not Proved According to IQWiG

In an evaluation in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) recently assessed whether IBD drug Entyvio (vedolizumab) from Takeda Pharma (TYO: 4502), Japan’s largest drug maker, offers additional benefits over standard therapies. The conclusion reached by the IQWiG was that the therapeutic benefits of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *